Labiotech.eu

News and Trends 20 Jul 2023

Endometrial cancer drug receives breakthrough therapy designation in China

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

July 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Seven pharma companies form alliance to prepare for future pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Biomica announces interim positive results from irritable bowel syndrome program

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Sosei Heptares hails ‘transformational’ acquisition

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

In Depth 19 Jul 2023

Genetic engineering giants: is China poised to lead the way?

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

July 19, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 19 Jul 2023

Novel bacterial communication system could help take on antimicrobial resistance

A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […]

July 19, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jul 2023

Moleculin issues acute myeloid leukemia drug data

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

July 19, 2023 - 3 minutesmins - By Jim Cornall

Ziwig revolutionizes endometriosis diagnosis

In Depth 18 Jul 2023

Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test

A condition that affects around 190 million women and girls worldwide, according to the World Health Organization, endometriosis is a chronic, difficult-to-treat disease that causes debilitating pelvic pain. Often misdiagnosed as irritable bowel syndrome (IBS) and sometimes dismissed as menstrual cramps, the diagnosis of endometriosis can take around 10 years, raising the severity of the […]

July 18, 2023 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 18 Jul 2023

Korro Bio and Frequency Therapeutics to merge

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]

July 18, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 18 Jul 2023

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 18 Jul 2023

FDA approves Beyfortus ahead of 2023-24 RSV season

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Endometrial cancer drug receives breakthrough therapy designation in China

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Seven pharma companies form alliance to prepare for future pandemics

Biomica announces interim positive results from irritable bowel syndrome program

Sosei Heptares hails ‘transformational’ acquisition

Genetic engineering giants: is China poised to lead the way?

Novel bacterial communication system could help take on antimicrobial resistance

Moleculin issues acute myeloid leukemia drug data

Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test

Korro Bio and Frequency Therapeutics to merge

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

FDA approves Beyfortus ahead of 2023-24 RSV season

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!